Trial Profile
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
- Indications Graft-versus-host disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms GRAVITAS-309
- Sponsors Incyte Corporation
- 13 Mar 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 23 Jan 2024 Status changed from active, no longer recruiting to discontinued (due to insufficient efficacy to support moving into Part 2 of thestudy).
- 13 Jan 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.